Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
BackgroundRipretinib has been approved for the treatment of gastrointestinal stromal tumors (GIST). As a novel therapy, several adverse reactions remain unidentified, necessitating a thorough safety evaluation. This study analyzes real-world data from the US Food and Drug Administration Adverse Even...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1542315/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | BackgroundRipretinib has been approved for the treatment of gastrointestinal stromal tumors (GIST). As a novel therapy, several adverse reactions remain unidentified, necessitating a thorough safety evaluation. This study analyzes real-world data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) to investigate adverse events (AEs) associated with ripretinib.MethodsAdverse event reports (AERs) related to ripretinib were extracted from FAERS ASCII data spanning from the second quarter of 2020 to the second quarter of 2024. Following standardization, various disproportionality analyses, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), bayesian confidence propagation neural network (BCPNN), and empirical bayes geometric mean (EBGM), were employed to identify potential safety signals linked to ripretinib. The data provided by medical professionals underwent sensitivity analysis to assess the robustness of the results.ResultsA total of 3,105 ripretinib-related AERs were identified, categorized into 22 system organ classes (SOCs) and 84 preferred terms (PTs). Common AEs, such as alopecia, constipation, and muscle spasms, were consistent with the drug label and clinical trial findings. Notably, the risk of skin cancer associated with ripretinib was further elucidated. Additionally, new signals, including liver abscess and prostatomegaly, were detected. Despite their lower frequency, these signals demonstrated significant strength. A substantial proportion of adverse reactions (n = 322, 39.80%) occurred within the first month of treatment, although a smaller fraction emerged after one year. The sensitivity analysis revealed that most PTs related to skin and subcutaneous tissue maintained high signal values, with 8 cases of skin squamous cell carcinoma-related AEs still reported.ConclusionThe findings of this study align with established drug guidance and uncover new adverse event signals for ripretinib, thereby enhancing clinical monitoring and facilitating risk identification. |
|---|---|
| ISSN: | 2234-943X |